Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.
Inflamm Bowel DisSep 1, 2026
Anita Afzali, Silvio Danese, Remo Panaccione et al.
✦ AI-curated · Sources linked
In 30 seconds
The phase 2 GALAXI 1 trial assessed the long-term efficacy and safety of guselkumab in patients with moderately to severely active Crohn's disease. Among participants continuing treatment for 5 years, 97.7% achieved clinical remission, while 71.3% and 51.7% achieved endoscopic response and remission, respectively. The study highlights the sustained efficacy of guselkumab over time.
Key findings
- 97.7% of participants achieved clinical remission at week 240.
- 71.3% achieved endoscopic response at week 240.
- 51.7% achieved endoscopic remission at week 240.
- Low rates of serious adverse events were reported.
Why it matters
The findings indicate that guselkumab provides sustained efficacy in managing Crohn's disease, which is crucial for improving patient outcomes and quality of life. Understanding long-term treatment options can help clinicians make informed decisions for their patients.